Nexentis subsidiary MitoCareX Bio completes initial AI drug screening with Boltz
NXTS•Nexentis Technologies' wholly owned subsidiary MitoCareX Bio completed initial computational screening in an AI-driven drug discovery initiative with Boltz. The preliminary predictions require further computational analysis and experimental validation.
1. Screening completed
MitoCareX Bio completed initial computational screening in its AI-driven drug discovery initiative with Boltz. Launched in June 2026, the initiative targets potential small-molecule starting points for selected discovery programs.
2. Further validation needed
The preliminary predictions require further computational analysis and experimental validation before any program advances. MitoCareX retains control over its discovery programs and any small-molecule candidates advanced through the initiative.
